Ruthigen, Inc.

Ruthigen, Inc. is a biotechnology firm dedicated to developing pharmaceutical-grade antimicrobial solutions aimed at preventing infections during surgical and trauma procedures. Founded in Santa Rosa, US, Ruthigen, Inc. specializes in infection prevention technologies.

The company underwent a merger with Pulmatrix in March 2015, a move to enhance its product offerings. The current CEO and founder information is not publicly available. Ruthigen, Inc. develops and commercializes RUT58-60, a hypochlorous acid-based drug candidate designed to prevent and treat infections in surgical settings.

This broad-spectrum antimicrobial solution is effective against various pathogens, including antibiotic-resistant strains, aiming to reduce postoperative complications and accelerate healing. Ruthigen generates revenue through direct sales of RUT58-60 to healthcare facilities, integrating this product into existing infection prevention protocols. Revenue hinges on the adoption rate of RUT58-60, particularly in high-risk abdominal surgeries, supported by pricing based on bulk agreements and institutional contracts. Ruthigen plans to expand the applications of RUT58-60 beyond abdominal surgeries, aiming for broader usage in various surgical procedures.

The company is targeting international markets including Canada, the European Union, and Japan. The merger with Pulmatrix in March 2015 is expected to bolster these strategic initiatives, leveraging combined resources to accelerate product development and market entry.